FDA approves Edwards' porcine replacement heart valve:
This article was originally published in Clinica
The US FDA has approved Edwards Lifesciences' Carpentier-Edwards SAV porcine replacement heart valve, which the firm says has a 20-year history outside of the US. The bioprosthesis allows for supra-annular implantation - above a patient's native aortic valve, rather than directly into the aortic annulus - and a proprietary scalloped sewing band for optimising anatomic fit. Supra-annular placement allows surgeons to implant a larger-orifice valve, which provides improved haemodynamic performance over intra-annularly placed porcine aortic heart valves, explains the Irvine, California firm. The valve also features Edwards' XenoLogiX tissue treatment.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.